Strategic Shifts at Bayer: Navigating Pricing and Production Challenges

Bayer plans US manufacturing shift and higher European drug prices to counter US policy risks and patent expirations, focusing on key pipeline drugs.

Pharmaceutical giant Bayer is undertaking a significant strategic realignment in response to mounting geopolitical and commercial pressures. The company is evaluating an expansion of its manufacturing footprint within the United States while simultaneously pushing for higher drug prices in Europe. These moves are a direct response to evolving U.S. trade and pricing policies, which threaten to reshape the industry's global financial landscape.

A Dual-Pronged Strategy for Revenue and Risk

Facing the prospect of new U.S. regulations that could tie domestic drug prices to international benchmarks, Bayer's pharmaceutical division head, Stefan Oelrich, is proactively engaging with European governments. The objective is to secure premium pricing for new drug launches on the continent. The underlying calculation is straightforward: if profit margins in the critical U.S. market come under pressure, revenue must increase elsewhere to sustain the massive research and development budgets required in the sector.

Concurrently, the company is considering shifting a portion of its production capacity to U.S. soil. This potential relocation aims to mitigate risks associated with punitive tariffs, a path already being taken by several competitors who have recently announced multi-billion dollar investments in American manufacturing. Bayer's distribution and research operations are already heavily concentrated in North America, making such a transition more feasible.

Pipeline Priorities and the Patent Cliff

Beyond these macro-strategic concerns, Bayer's core operational focus remains on navigating a challenging period of patent expirations. The pharmaceuticals unit is targeting mid-single-digit sales growth and an approximate 30% profit margin by the end of the decade. This ambition rests on the shoulders of five key pipeline drugs, including the cancer treatment Nubeqa and the kidney disease therapy Kerendia. These products are crucial to offsetting anticipated steep revenue declines for older blockbusters.

Significant drops are forecast for two major existing products: a decline of up to 25% for the eye medicine Eylea by 2026, and a potential fall of up to 40% for the top-selling anticoagulant Xarelto. While Oelrich has not ruled out targeted acquisitions to bolster the pipeline, he emphasizes that any such moves would be highly selective.

Upcoming Catalysts and Financial Strain

These ambitious plans unfold against a backdrop of continued financial pressure. Although Bayer managed to reduce its net debt to approximately €29.8 billion by the end of 2025, the current year is expected to see deeply negative free cash flow. This is largely due to litigation-related payouts, which alone are projected to consume around €5 billion.

Investors are closely watching three key dates in the coming weeks:
* April 24, 2026: A virtual Annual General Meeting, where shareholders will vote on a proposed dividend of €0.11 per share.
* April 27, 2026: Oral arguments before the U.S. Supreme Court in the ongoing Roundup litigation.
* May 12, 2026: Publication of the company's first-quarter financial results.

The Supreme Court hearing carries particularly substantial weight for Bayer's future. The U.S. government, under the Trump administration, has filed a brief in support of Bayer's position regarding alleged inadequate warning labels. A final ruling, expected in the latter half of June, could determine whether the company can establish a legal precedent that would effectively nullify the basis for thousands of future U.S. lawsuits.